What are the indications, dosing regimen, contraindications, and monitoring recommendations for naltrexone?

Naltrexone: Clinical Overview

Naltrexone is a mu-opioid receptor antagonist FDA-approved for treating alcohol use disorder and opioid dependence, with standard dosing of 50 mg daily orally or 380 mg monthly by injection (Vivitrol). 1

Indications

Naltrexone has two FDA-approved indications:

• Alcohol use disorder: 50 mg daily for maintaining abstinence 1
• Opioid dependence: Maintaining abstinence in motivated, opioid-free patients 2

The medication works best in highly motivated populations (such as healthcare professionals) who cannot or prefer not to take opioid agonist therapy 2. However, it has shown limited success in less motivated patient groups 2.

Dosing Regimen

For Alcohol Use Disorder

• Standard dose: 50 mg once daily 1
• Duration studied: up to 12 weeks in placebo-controlled trials 1

For Opioid Dependence

• Initiation: Start with 25 mg on day 1 1
• Maintenance: If no withdrawal occurs, advance to 50 mg daily 1
• Alternative supervised dosing:
  • 100 mg on Monday and Wednesday, 150 mg on Friday 2
  • 100 mg every other day
  • 150 mg every third day 1

Critical caveat: Extended dosing intervals above 50 mg carry higher risk of hepatotoxicity 1.

Contraindications and Critical Safety Requirements

Absolute Requirements Before Initiation

Patients MUST be completely opioid-free before starting naltrexone 1. This is non-negotiable:

• Minimum 7-10 days opioid-free for short-acting opioids 1
• Up to 2 weeks for patients transitioning from buprenorphine or methadone 1
• This includes tramadol 1

Naloxone Challenge Test

Perform this test if any doubt exists about opioid-free status 1:

IV route:

• Inject 0.2 mg naloxone, observe 30 seconds
• If no withdrawal, inject 0.6 mg, observe 20 minutes

Subcutaneous route:

• Administer 0.8 mg naloxone, observe 20 minutes

If withdrawal signs appear (nausea, vomiting, sweating, craving, pupillary dilation, anxiety, muscle aches): DO NOT start naltrexone. Repeat challenge in 24 hours 1.

Absolute Contraindications

• Current opioid use or dependence 1
• Patients requiring opioid analgesics (naltrexone blocks pain relief from opioids) 2
• Acute opioid withdrawal 1
• Positive urine opioid screen 1

Monitoring Requirements

Hepatic Monitoring

Obtain liver function tests at baseline and every 3-6 months 2. Naltrexone causes dose-related hepatocellular injury at supratherapeutic doses (above 50 mg) 1. While standard 50 mg daily dosing is generally safe, hepatotoxicity remains the primary serious adverse effect requiring surveillance 1.

Suicide Risk Monitoring

Depression and suicidal ideation occur in 0-15% and 0-1% respectively in patients treated for alcoholism (similar to placebo rates of 0-17% and 0-3%) 1. Naltrexone does not reduce suicide risk—maintain standard psychiatric monitoring 1.

Common Adverse Effects to Monitor

Most frequent (>10%): insomnia, anxiety, nervousness, abdominal pain/cramps, nausea/vomiting, low energy, joint/muscle pain, headache 1

Less common (2-10%): dizziness, fatigue, somnolence 1

Important: Five patients discontinued in clinical trials due to nausea 1. Most adverse effects are mild and manageable.

Critical Clinical Pitfalls

Risk of Precipitated Withdrawal

The most dangerous error is starting naltrexone in patients not fully opioid-free. This precipitates severe withdrawal that can be medically serious 1. Postmarketing reports document severe precipitated withdrawal when switching from buprenorphine or methadone 1.

Loss of Opioid Tolerance

Patients who discontinue naltrexone face increased risk of opioid overdose and death due to decreased opioid tolerance during treatment 2. Counsel patients explicitly about this risk before stopping therapy.

Compliance Challenges

Naltrexone only works when taken consistently. Implement compliance-enhancing techniques as part of comprehensive addiction treatment 1. The medication is "of proven value only when given as part of a comprehensive plan of management that includes some measure to ensure the patient takes the medication" 1.

Treatment Context

Naltrexone should never be used as monotherapy. Success requires:

• Intensive behavioral therapy and counseling 2
• Community-based support groups 1
• Management of comorbid psychiatric conditions 1
• Strong family/social support systems 2

The medication is one component of a multimodal treatment approach—not a standalone cure for addiction 1.